haloperidol has been researched along with Bradykinesia in 13 studies
Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279)
haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We applied nicotine 21 mg and matching placebo transdermal patches to thirty haloperidol-treated patients with schizophrenia who smoked." | 9.10 | Nicotine decreases bradykinesia-rigidity in haloperidol-treated patients with schizophrenia. ( Kamaraju, L; McEvoy, JP; Nelson, L; Wilson, W; Yang, YK, 2002) |
| "In haloperidol-induced catalepsy in rats (1." | 5.30 | Effects of N-propargyl-1-(R)aminoindan (rasagiline) in models of motor and cognition disorders. ( Cohen, S; Levy, R; Speiser, Z, 1998) |
| "We applied nicotine 21 mg and matching placebo transdermal patches to thirty haloperidol-treated patients with schizophrenia who smoked." | 5.10 | Nicotine decreases bradykinesia-rigidity in haloperidol-treated patients with schizophrenia. ( Kamaraju, L; McEvoy, JP; Nelson, L; Wilson, W; Yang, YK, 2002) |
| " The extract at both the doses displayed a significant reduction in postural flexion, moderate decrease in tremor, muscular rigidity and postural immobility scores but do not exhibit significant lowering of hypokinesia score in reserpine induced Parkinsonian model." | 4.12 | Antiparkinsonian activity of Tabebuia impetiginosa bark and biochemical analysis of dopamine in rat brain homogenates. ( Kadiri, SK; Karkar, VV; Pal Roy, S; Rao Konijeti, S, 2022) |
| "3-3 mg/kg) did not induce EPS signs by itself; however, it significantly potentiated bradykinesia induction with a low dose of haloperidol (0." | 3.81 | Interaction between anti-Alzheimer and antipsychotic drugs in modulating extrapyramidal motor disorders in mice. ( Fujiwara, M; Mizuguchi, Y; Morimoto, T; Ohno, Y; Shimizu, S; Sobue, A, 2015) |
| " To evaluate the interactions between antipsychotics and drugs for mood disorders in modulating extrapyramidal side effects (EPS), we examined the effects of antidepressants and mood-stabilizing drugs on haloperidol (HAL)-induced bradykinesia and catalepsy in mice and rats." | 3.78 | Modulation of antipsychotic-induced extrapyramidal side effects by medications for mood disorders. ( Imaki, J; Ohno, Y; Sato, M; Shimizu, S; Shin, N; Sugiuchi, T; Tatara, A, 2012) |
| "We examined the effects of JP-1302 (a selective alpha2C antagonist), BRL-44408 (a selective alpha2A antagonist) and yohimbine (a non-selective alpha2 antagonist) on haloperidol-induced bradykinesia and catalepsy in mice to elucidate the role of alpha2 adrenoceptor subtypes in modifying extrapyramidal motor disorders." | 3.75 | Therapeutic potential of alpha2 adrenoceptor antagonism for antipsychotic-induced extrapyramidal motor disorders. ( Imaki, J; Mae, Y; Ohno, Y; Shimizu, S, 2009) |
| "Bradykinesia was also associated with decreased intensity of bursting and amplitude of cross-correlation peaks at rest." | 1.33 | Bradykinesia induced by dopamine D2 receptor blockade is associated with reduced motor cortex activity in the rat. ( Hyland, BI; Parr-Brownlie, LC, 2005) |
| " These findings suggest that acute dystonia is affected by age factor, and that daily dosage or monitoring of drug concentration is unlikely to be a useful marker for the prediction of side-effects during bromperidol treatment." | 1.31 | The characteristics of side-effects of bromperidol in schizophrenic patients. ( Ishida, M; Kaneko, S; Kondo, T; Mihara, K; Otani, K; Tanaka, O; Yasui-Furukori, N, 2002) |
| "In haloperidol-induced catalepsy in rats (1." | 1.30 | Effects of N-propargyl-1-(R)aminoindan (rasagiline) in models of motor and cognition disorders. ( Cohen, S; Levy, R; Speiser, Z, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (7.69) | 18.2507 |
| 2000's | 6 (46.15) | 29.6817 |
| 2010's | 3 (23.08) | 24.3611 |
| 2020's | 3 (23.08) | 2.80 |
| Authors | Studies |
|---|---|
| Pal Roy, S | 1 |
| Kadiri, SK | 1 |
| Karkar, VV | 1 |
| Rao Konijeti, S | 1 |
| Reakkamnuan, C | 1 |
| Kumarnsit, E | 1 |
| Cheaha, D | 1 |
| Hussain, S | 1 |
| Villarreal, S | 1 |
| Ramirez, N | 1 |
| Hussain, A | 1 |
| Sumaya, IC | 1 |
| Shimizu, S | 5 |
| Sogabe, S | 1 |
| Yanagisako, R | 1 |
| Inada, A | 1 |
| Yamanaka, M | 1 |
| Iha, HA | 1 |
| Ohno, Y | 5 |
| Mizuguchi, Y | 1 |
| Sobue, A | 1 |
| Fujiwara, M | 1 |
| Morimoto, T | 1 |
| Imaki, J | 3 |
| Mae, Y | 1 |
| Tatara, A | 1 |
| Shin, N | 1 |
| Sato, M | 1 |
| Sugiuchi, T | 1 |
| Yang, YK | 1 |
| Nelson, L | 1 |
| Kamaraju, L | 1 |
| Wilson, W | 1 |
| McEvoy, JP | 1 |
| Parr-Brownlie, LC | 1 |
| Hyland, BI | 1 |
| Ishihara, S | 1 |
| Sofue, N | 1 |
| Sasa, M | 1 |
| Kawai, Y | 1 |
| Speiser, Z | 1 |
| Levy, R | 1 |
| Cohen, S | 1 |
| Fitzgerald, PB | 1 |
| Kapur, S | 1 |
| Caligiuri, MP | 1 |
| Jones, C | 1 |
| Silvestri, S | 1 |
| Remington, G | 1 |
| Zipursky, RB | 1 |
| Yasui-Furukori, N | 1 |
| Kondo, T | 1 |
| Ishida, M | 1 |
| Tanaka, O | 1 |
| Mihara, K | 1 |
| Kaneko, S | 1 |
| Otani, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Transdermal Nicotine in Female Patients at High Risk for PONV[NCT00775749] | 0 participants (Actual) | Interventional | 2009-04-30 | Withdrawn (stopped due to The study is not feasible with the number of subjects needed to complete it.) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for haloperidol and Bradykinesia
| Article | Year |
|---|---|
Nicotine decreases bradykinesia-rigidity in haloperidol-treated patients with schizophrenia.
Topics: Administration, Cutaneous; Adult; Anti-Dyskinesia Agents; Brain; Female; Haloperidol; Humans; Hypoki | 2002 |
Instrumentally detected changes in motor functioning in patients with low levels of antipsychotic dopamine D2 blockade.
Topics: Adult; Carbon Radioisotopes; Cerebellum; Corpus Striatum; Dopamine Antagonists; Dopamine D2 Receptor | 2000 |
11 other studies available for haloperidol and Bradykinesia
| Article | Year |
|---|---|
Antiparkinsonian activity of Tabebuia impetiginosa bark and biochemical analysis of dopamine in rat brain homogenates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adjuvants, Immunologic; Animals; Antioxidants; Antipar | 2022 |
Local field potential (LFP) power and phase-amplitude coupling (PAC) changes in the striatum and motor cortex reflect neural mechanisms associated with bradykinesia and rigidity during D2R suppression in an animal model.
Topics: Animals; Catalepsy; Corpus Striatum; Haloperidol; Hypokinesia; Male; Mice; Models, Animal; Motor Cor | 2023 |
Haloperidol-induced hypokinesia in rats is differentially affected by the light/dark phase, age, and melatonin.
Topics: Age Factors; Animals; Behavior, Animal; Central Nervous System Depressants; Disease Models, Animal; | 2020 |
Glycine-Binding Site Stimulants of NMDA Receptors Alleviate Extrapyramidal Motor Disorders by Activating the Nigrostriatal Dopaminergic Pathway.
Topics: Animals; Binding Sites; Corpus Striatum; Cycloserine; Dizocilpine Maleate; Dopamine; Glycine; Halope | 2017 |
Interaction between anti-Alzheimer and antipsychotic drugs in modulating extrapyramidal motor disorders in mice.
Topics: Alzheimer Disease; Animals; Antipsychotic Agents; Basal Ganglia Diseases; Cholinesterase Inhibitors; | 2015 |
Therapeutic potential of alpha2 adrenoceptor antagonism for antipsychotic-induced extrapyramidal motor disorders.
Topics: Acridines; Adrenergic alpha-2 Receptor Antagonists; Adrenergic alpha-Antagonists; Analysis of Varian | 2009 |
Modulation of antipsychotic-induced extrapyramidal side effects by medications for mood disorders.
Topics: Animals; Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Behavior, Animal; Catalepsy; | 2012 |
Bradykinesia induced by dopamine D2 receptor blockade is associated with reduced motor cortex activity in the rat.
Topics: Animals; Disease Models, Animal; Dopamine; Dopamine D2 Receptor Antagonists; Electric Stimulation; H | 2005 |
Evaluation of the antibradykinetic actions of 5-HT1A agonists using the mouse pole test.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antipsychotic Agents; Behavior, Animal; Disease Mod | 2008 |
Effects of N-propargyl-1-(R)aminoindan (rasagiline) in models of motor and cognition disorders.
Topics: Aging; alpha-Methyltyrosine; Animals; Avoidance Learning; Catalepsy; Cognition; Cognition Disorders; | 1998 |
The characteristics of side-effects of bromperidol in schizophrenic patients.
Topics: Adult; Antipsychotic Agents; Dystonia; Female; Haloperidol; Humans; Hypokinesia; Male; Schizophrenia | 2002 |